Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
CVS Health said it is rebuilding a local playing field using a “Mini-Pitch System” in support of the Alex Morgan Foundation, as part of a broader, multi-year effort to revitalize sports facilities.
THE APEX TIMES
THE APEX TIMES
A new comparison of the two pharma giants highlights how expiring patents are forcing both companies to demonstrate that newer medicines can replace revenue from older blockbusters. The debate, investors note, is less about what the companies sold and more about what they can sell next.
THE APEX TIMES
Pfizer reported a modest year-over-year improvement in fiscal Q2 operations, indicating stabilization after the sharp contraction in pandemic-related demand. The market question now is whether the company’s pipeline and upcoming launches can offset the revenue pressure from an expected patent cliff.
THE APEX TIMES
A new proposal would resolve tens of thousands of lawsuits alleging Johnson & Johnson’s talc-based products contribute to ovarian cancer, but the broader pace of litigation and future claims remains the market focus.
THE APEX TIMES
A recent market piece on healthcare investing weighs J&J’s steady, diversified business against Thermo Fisher’s faster-linked growth from labs, clinical work, and manufacturing services, asking which pattern tends to hold up across cycles.
THE APEX TIMES
A recent market note argues that today’s leading obesity franchises still leave room for other approaches, pointing to Rhythm Pharmaceuticals as a potential beneficiary amid investor Stanley Druckenmiller’s renewed attention to the space.
THE APEX TIMES
A new market note frames Johnson & Johnson as a “dividend king” and sets up Abbott Laboratories as the key alternative, arguing the two have diverged in performance and outlook.
THE APEX TIMES
A market comparison pits Pfizer’s pipeline-driven effort to move past aging blockbuster revenue against Gilead’s push to broaden beyond HIV and build a wider portfolio. Much depends on how quickly newer medicines translate into sustained demand.
THE APEX TIMES
A recent market note says investors may be underestimating Eli Lilly’s near-term catalysts, even after the drugmaker posted one of Big Pharma’s most dramatic quarterly results.
